Pfizer price target raised to $26 from $25 at Wolfe Research

Wolfe Research analyst Alexandria Hammond raised the firm’s price target on Pfizer (PFE) to $26 from $25 and keeps an Underperform rating on the shares following what the firm calls “a rather uneventful print.” The revenue beat “likely warranted a guidance raise if it weren’t for the unpredictable COVID” business, says the analyst, who cites the five-year sales CAGR view and Vyndamax exclusivity to 2031 for the firm’s target raise.